308 results about "Autophagy" patented technology

The invention discloses an adipose-derived stem cell exosome compound loaded with silver nanoparticles and application of the adipose-derived stem cell exosome compound loaded with the silver nanoparticles, and ADSC-Exos loaded with the silver nanoparticles is developed by integrating AgNPs into an exosome of ADSCs. In vivo, the Exo-AgNPs can accelerate healing of infected wounds by reducing bacterial colonization and promoting collagen deposition, angiogenesis and M2 type macrophage polarization. In vitro, the Exo-AgNPs activates the functions of fibroblasts and vascular endothelial cells, and shows an excellent antibacterial property. In addition, the Exo-AgNPs induces polarization of M2 type macrophages and inhibits secretion of proinflammatory cytokines by activating autophagy. The results show that Exo-AgNPs is expected to become an ideal biological material for treating infected wounds.

The invention discloses an unmanned aerial vehicle remote sensing quantitative marine ecological restoration effect evaluation system, and relates to the technical field of marine ecological monitoring and evaluation, and the system comprises a rhythm resonance excitation module, a resonance coupling inversion module, an error autophagy verification module, and a resonance steady state adjustment module. According to the invention, a three-in-one framework of a rhythm resonance coupling mechanism, an error autophagy verification mechanism and a rhythm phase latch-cross-scale energy anchoring stator mechanism is utilized, and four core modules of rhythm resonance excitation, resonance coupling inversion, error autophagy verification and resonance steady state adjustment are combined. The method solves the problems of low evaluation precision, no self-verification capability and large errors caused by marine environment interference due to manual sampling recheck and rhythm splitting in the prior art, realizes quantitative evaluation and self-verification of the marine ecological restoration effect without manual sampling, remarkably improves evaluation efficiency, credibility and precision, and is suitable for large-scale popularization and application. And micro-scale power data can be synchronously output, the endurance of the unmanned aerial vehicle is prolonged, and the restoration trend is pre-judged.

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

Described herein are compounds that are inhibitors of autophagy and their use in the treatment of disorders such as cancers.

A novel autophagy activator is provided. An autophagy activator, a hyaluronic acid production promoter, and an antioxidant, each of which contains a lactic acid fermentation product obtained by fermenting a raw material derived from a tea tree with lactic acid bacteria.

The invention discloses a magnetic-aptamer targeting tumor tissue nano-drug delivery system as well as a preparation method and application thereof, and belongs to the field of medicines. The system comprises a mesoporous ferroferric oxide magnetic core, a polyethyleneimine (PEI) layer coated outside the mesoporous ferroferric oxide magnetic core and an aptamer adsorbed outside the PEI layer, and an autophagy activator can be selectively loaded in the mesoporous core. The preparation method comprises the following steps: sequentially carrying out drug loading, PEI coating and aptamer modification on the mesoporous Fe3O4 nanoparticles. According to the invention, efficient enrichment and endocytosis of tumor tissues are realized through dual effects of magnetic targeting and active targeting of the aptamer; lysosome escape is promoted by using the proton sponge effect of PEI; finally, by virtue of the synergistic effect of iron ions released by degradation of the Fe3O4 nanoparticles and endogenous iron ions released by ferritin autophagy induced by an autophagy activator, ferroptosis of tumor cells is induced through enhanced Fenton-like reaction, so that high-efficiency and low-toxicity targeted therapy is realized.

The invention belongs to the technical field of biological medicine, and relates to application of a compound D25, in particular to application of a small molecule compound D25 in preparation of a product for preventing or treating Alzheimer's disease (AD), and the structural formula of the compound is shown in the specification. Experiments prove that the small molecule compound D25 can pass through a blood brain barrier, can induce autophagy, can relieve pathological characteristics of an AD mouse model and improve cognitive impairment of the AD mouse model, can reduce the proportion of disease-related microglial cells by recovering the morphology of the microglial cells and improving the A beta phagocytosis capacity of the microglial cells, has the potential of promoting neuronal growth and increasing the number of protrusions, and can be used for preparing a medicine for treating the disease-related microglial cells. Therefore, AD can be effectively treated, the safety is high, the effect is achieved, and the application prospect is great.

Provided are methods for treating a disease or condition associated with reduced autophagy in a patient, which includes administering to the patient, either simultaneously or sequentially, a therapeutically effective amount of a synergistic combination of compounds from at least two and preferably three of the classes of compounds selected from a saccharide, a vitamin, a ketone body, a polyphenol, and a methylxanthine. The compounds may be present in a subtherapeutic effective amount relative to the compound's dosing when given as a single agent. Also provided are pharmaceutically acceptable compositions and kits including at least two and preferably three of the named classes of compounds.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The invention discloses a stably transfected cell strain for evaluating fibroblast autophagy flux and a construction method of the stably transfected cell strain. The construction method comprises the following step: infecting fibroblasts by using HBAD (Hepatitis B Antigen)-red fluorescent protein-EGFP-LC3 autophagy double-labeled adenovirus. The construction method can be combined with a super-resolution microscope to dynamically observe the autophagy intensity change in the primary fibroblasts through an imaging method.

A series of 1, 3, 5-triazine compounds that exhibit potent inhibition of endosomal trafficking and autophagy is provided. These compounds effectively suppress cancer cell proliferation, growth, and migration, induce cell cycle arrest at the G0 / G1 phase, promote cancer cell death via non-apoptotic pathways, and inhibit tumor sphere formation. Moreover, select compounds within this series demonstrate significant inhibition of tumor growth and metastasis in mouse models of lung cancer and melanoma. Additionally, they modulate macrophage polarization and the tumor microenvironment by regulating cytokine secretion. These findings highlight the potential of 1, 3, 5-triazine compounds as promising antitumor agents.

The invention discloses an oral hard capsule health-care product with an anti-aging function as well as a preparation method and application of the oral hard capsule health-care product. The health-care product is mainly prepared from eight active ingredients including EGT (Ergothioneine), Ca-AKG (alpha-ketoglutarate), PQQ (pyrroloquinoline quinone), fisetin, salidroside, urolithin A, spermidine and an apple stem cell extract. Through scientific compatibility of the various components, the composition disclosed by the invention can comprehensively intervene in a cell aging process through a synergistic effect of a plurality of pathways of enhancing the cell antioxidant capacity, improving the mitochondrial function, activating cell autophagy, promoting cell regeneration and repair and the like. The invention also provides a preferred content range of the health-care product, a preparation method of the health-care product and application of the health-care product in preparation of health-care foods for delaying senescence, improving cell viability or improving mitochondrial functions. The product provided by the invention has the characteristics of multiple targets and synergistic interaction, and provides a new effective scheme for anti-aging intervention.

The invention relates to the technical field of biological medicines, and particularly discloses application of ebbeselenium in preparation of a medicine for treating male delayed gonadal hypofunction. After the ebbeselenium is adopted for intervention, the autophagy activity of testicular interstitial cells of old mice is increased, lipid autophagy is enhanced, testosterone synthesis is promoted, the serum testosterone level is remarkably improved, and the symptoms of male delayed hypogonadism (LOH) are effectively relieved; ebbeselenium simultaneously shows a relatively good delaying effect on senescence of a plurality of organs. The ebbeselenium can improve the reproductive capacity, the behavior memory capacity, the athletic capacity and the metabolic function of old mice at the same time, and synergistic and effective treatment of low serum testosterone and LOH complications is achieved. Besides, by enhancing the molecular reduction effect of PRDX1 targeting ATG4B, the ebbeselenium regulates and controls the autophagy pathway of testicular interstitial cells and enhances the functions of the testicular interstitial cells so as to promote synthesis of testosterone, and a new treatment strategy is provided for treatment of LOH.

The application discloses a combined drug for treating lung cancer. It is found for the first time that lomethixol can be used alone or in combination with other drugs to have a significant anticancer effect on NSCLC patients and NSCLC patients resistant to osimertinib, and in addition, it is found that lomethixol is a potential autophagy inducer and can activate cell autophagy. The application provides a new clinical treatment method for NSCLC patients and NSCLC patients resistant to osimertinib, and has a wide application prospect.

The invention discloses an application of ametinib in preparation of a medicine for treating liver cancer, belongs to the technical field of new application of medicines, and verifies the potential of third generation EGFR-TKI ametinib in inhibiting liver cancer progression in vivo and in vitro, and cell function experiments prove that ametinib can effectively inhibit proliferation, migration and invasion ability of liver cancer cells; the exact type of ametinib for inducing liver cancer cell death is determined, and ametinib inhibits survival and proliferation of liver cancer cells by activating autophagy and inducing ferroptosis; the application proves that autophagy activated by the ametinib can promote the occurrence of ferroptosis by regulating and controlling the degradation of GPX4 (glutathione peroxidase 4) and the accumulation of reactive oxygen species (ROS), and the ametinib inhibits the progress of liver cancer by inducing autophagy-dependent ferroptosis, so that the ametinib is used for preparing the medicine for treating liver cancer.

The invention provides an application of an ASPL-TFE3 fusion gene in preparation of a medicine for enhancing the curative effect of an immune checkpoint inhibitor. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The invention relates to the field of tumor immunotherapy, in particular to a method for regulating and controlling expression and activity of TFE3 through ASPL-TFE3 fusion protein to enhance tumor cell autophagy and immune cell permeation, and the tumor treatment effect of an immune checkpoint inhibitor can be improved.

The invention relates to the fields of pharmacology and molecular biology, and discloses an autophagy inhibitory polypeptide competitively combined with an LIR docking site of an autophagy-related protein LC3 and application of the autophagy inhibitory polypeptide. Through molecular docking simulation, through LIR docking sites of targeted LC3 protein, 794 bioactive polypeptides which can be combined are screened out. Functional result analysis shows that peptide 3 #, peptide 4 # and peptide 5 # are competitively combined with LIR docking sites of the LC3 protein, so that formation of autophagy vesicles is inhibited in a targeted manner, and proliferation and survival of autophagy-dependent pancreatic cancer cells are effectively inhibited; the strategy is combined with chemotherapeutic drugs to show a synergistic effect, and the pancreatic cancer resisting curative effect is remarkably enhanced.

This invention relates to the field of cosmetic compositions, and more specifically to a synergistic anti-aging composition involving energy metabolism and autophagy, its preparation method, and its application. The composition comprises sea buckthorn fruit extract, trehalose, and a cosmetically acceptable polyol carrier. This invention pioneers a betaine-trehalose-NADES extraction system, achieving low-temperature, high-efficiency extraction while preserving the heat-sensitive active ingredients of sea buckthorn. Trehalose possesses both extraction and autophagy activation effects. A selective separation strategy achieves a balance between efficacy, compliance, and process simplicity. The green, circular process reduces costs and is environmentally friendly. Through the synergistic effect of sea buckthorn fruit extract and trehalose, the composition enhances mitochondrial membrane potential, increases ATP production, inhibits excessive activation of the mTOR pathway, and promotes LC3-II conversion, thus synergistically combating skin aging from multiple targets including cellular energy metabolism, signaling pathways, and autophagy.

The present invention belongs to the field of biomedicine technology, and relates to the application of the Lnc-FLJ gene in the treatment of castration-resistant prostate cancer. The application of the Lnc-FLJ gene inhibitor in the preparation of prostate cancer drugs. The present invention discovered for the first time that Lnc-FLJ can inhibit the proliferation and autophagy of castration-resistant prostate cancer. Lnc-FLJ is more highly expressed in castration-resistant prostate cancer cells and prostate cancer tissues with higher malignancy. Inhibiting Lnc-FLJ can inhibit the occurrence and development of castration-resistant prostate cancer. The preparation of Lnc-FLJ small molecule inhibitor shRNA is used to treat castration-resistant prostate cancer and cancer insensitive to enzalutamide, thereby inhibiting the AR signaling pathway. The present invention provides new ideas for further studying the pathogenesis of castration-resistant prostate cancer and the function of the Lnc-FLJ gene, and provides a new direction for the development of castration-resistant prostate cancer drugs.

The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and / or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and / or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and / or an agent that treats, ameliorates, and / or prevents one or more virus infection symptoms and / or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors / antagonists that cause and / or trigger ER stress and / or autophagy are useful within the methods of the disclosure.

The invention relates to the technical field of poultry breeding, and particularly provides a novel application of miR-17-5p in chicken follicular development. Experiments prove that the miR-17-5p can inhibit autophagy and apoptosis of chicken follicular granular cells, so that granular cell proliferation can be promoted by promoting expression of the miR-17-5p in the chicken follicular granular cells, development of chicken ovary follicles is further promoted, and atresia is prevented. The invention also discovers that downstream target mRNA of miR-17-5p is MAP3K5, and researches find that MAP3K5 can promote autophagy and apoptosis of chicken follicular granular cells. The discovery provides a new thought for targeting particle cells to regulate dynamic balance between autophagy and apoptosis of the cells so as to improve the poultry breeding efficiency, and also expands the functional cognition of the JNK / BCL2 pathway in poultry research.

The invention relates to a truffle composition as well as a preparation method and application thereof, and belongs to the technical field of daily chemical products. The invention provides a truffle composition which comprises a truffle extract, retinol and nonapeptide-1, and the mass ratio of the truffle extract to the retinol to the nonapeptide-1 is as follows: the truffle extract to the retinol to the nonapeptide-1 is (0.026-200): (0.005-4): 1. The truffle extract disclosed by the invention has the effects of resisting inflammation, resisting oxidation, tightening and resisting wrinkles, and autophagy and brightening, and the retinol has the effects of tightening and resisting wrinkles; the nonapeptide-1 serving as a rhythm peptide has a rhythm rejuvenation effect, and the three components are matched to form the truffle composition which can synergistically improve a retinol metabolic pathway, accurately regulate and control retinol metabolism to remove oxidative damage, regulate and control anti-aging genes and collagen genes of skin and synergistically realize an anti-aging effect.

The invention relates to a brightening composition for improving skin transparency and glossiness and application of the brightening composition, and belongs to the technical field of cosmetics. The brightening composition comprises oxyresveratrol, a loquat leaf extract, a burdock seed extract and a verbascos extract, the composition can effectively resist oxidation and inflammation through the oxyresveratrol so as to relieve skin darkness, and the loquat leaf extract can promote cell autophagy so as to remove metabolic waste and improve skin permeability. The burdock seed extract improves the epidermis structure so as to enhance the skin light transmission, and the verbascos extract plays a role in instant brightening through a quantum transition effect. According to the composition, through the synergistic effect of all the components, the skin transparency and glossiness are remarkably improved, and the composition is mild, free of irritation and suitable for being used by people with sensitive skin.

The invention discloses a medicine for preventing or treating liver toxic and side effects of osimertinib, and belongs to the technical field of medicines. Aiming at liver toxic and side effects caused by osimertinib, the invention provides an effective therapeutic drug, and the autophagy inhibitor relieves death caused by excessive activation of an autophagy pathway in hepatocytes by inhibiting autophagy activated by osimertinib, so that hepatotoxicity caused by osimertinib is relieved. The autophagy inhibitor and osimertinib are combined, so that the survival rate of hepatocytes can be remarkably improved, and liver injury caused in the osimertinib treatment process is reduced. The invention further provides novel application of the hydroxychloroquine or the S-adenosylmethionine in preparation of the medicine for preventing or treating the liver toxic and side effects of the osimertinib, the hydroxychloroquine or the S-adenosylmethionine has a remarkable treatment effect on liver injuries caused by the osimertinib, the medication safety of the hydroxychloroquine or the S-adenosylmethionine is high, and the hydroxychloroquine or the S-adenosylmethionine can be used for preparing the medicine for preventing or treating the liver toxic and side effects of the osimertinib. Good development prospects are realized.

The invention relates to an effect of an REV-ERBalpha agonist SR9009 in the aspect of delaying ovarian senescence, and aims at the problem of fertility decline caused by cliff-type decline of ovarian functions of women over 35 years old, the SR9009 is applied to activate an REV-ERBalpha circadian rhythm signal channel in ovarian tissues, inhibit excessive autophagy of granular cells and maintain a primordial follicle dormancy state, so that the agonist SR9009 can be used for delaying ovarian senescence. Therefore, the original follicle depletion speed is delayed, follicle storage is maintained, and the ovary reproductive function cycle is prolonged. The effect is verified by a mammal model: REV-ERBalpha protein expression in an ovary of an aging individual is reduced, rhythmicity expression is disordered, autophagy of granulosa cells can be effectively inhibited in the ovary of the aging individual intervened by the SR9009, and the number of residual primordial follicles and the number of total follicles are obviously greater than those of an untreated control group. The invention provides an innovative treatment strategy of targeted rhythm regulation and control for clinical intervention of ovarian aging.

The present invention relates to compounds of Formula (I) and their use in the detection and monitoring of autophagic activity, as well as their use in the identification, treatment, prevention, or amelioration of diseases associated with dysregulation of autophagy.

The invention discloses double-response hydrogel as well as a preparation method and application thereof. The double-response hydrogel comprises a three-dimensional porous network hydrogel matrix, and tea polyphenol and nano silicon nitride which are loaded in the hydrogel matrix, the three-dimensional porous network hydrogel matrix is prepared from o-nitrobenzene grafted hyaluronic acid and carboxyl phenylboronic acid modified methyl chitosan. According to the hydrogel disclosed by the invention, in a low-pH / high-ROS microenvironment of a diabetic periodontitis focus, boric acid ester bonds are broken, tea polyphenol is released, and the tea polyphenol plays an anti-inflammatory role by efficiently removing active oxygen and inhibiting inflammatory factors; meanwhile, the Schiff base bond is dissociated to release the nano silicon nitride, and the nano silicon nitride significantly promotes angiogenesis and osteogenic differentiation and accelerates bone defect repair by activating a redox signal, inducing cell autophagy, regulating metabolic reprogramming and other pathways.

In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.

The invention discloses application of a composition containing lycium barbarum polysaccharide. The lycium barbarum polysaccharide is used for achieving the effects of resisting aging and removing lipofuscin, particularly, the specific lycium barbarum polysaccharide LBP1C can more remarkably reduce the level of transcription factors GATA4, activate key transcription regulatory factors of autophagy, reduce aging-related secretion phenotypes and inhibit accumulation of lipofuscin, and the lycium barbarum polysaccharide LBP1C has the effects of delaying aging, whitening skin and promoting healthy aging.